Invention Grant
- Patent Title: Heterocyclyl substituted pyrrolopyridines that are inhibitors of the CDK12 kinase
-
Application No.: US16649512Application Date: 2018-09-21
-
Publication No.: US11407767B2Publication Date: 2022-08-09
- Inventor: David Brook , Chris Hayes , Nicholas Bennett , Matthew Palframan , Sue Cramp , Richard Bull , Michael Bodnarchuk
- Applicant: The University of Nottingham
- Applicant Address: GB Nottingham
- Assignee: The University of Nottingham
- Current Assignee: The University of Nottingham
- Current Assignee Address: GB Nottingham
- Agency: Klarquist Sparkman, LLP
- Priority: GB1715342 20170922
- International Application: PCT/GB2018/052697 WO 20180921
- International Announcement: WO2019/058132 WO 20190328
- Main IPC: C07D401/14
- IPC: C07D401/14 ; C07D471/04 ; C07D519/00 ; A61K31/437 ; A61P33/02 ; A61P35/04
Abstract:
This invention related to compounds that are inhibitors of the CDK12 kinase. The compounds are useful in the treatment of disorders mediated by the CDK12 kinase including myotonic dystrophy type 1 (DM1) and other disorders caused by the generation of RNA repeat expansion transcripts. In particular, the invention relates to compounds of the formula (I), or a pharmaceutically acceptable salts or N-oxides thereof, wherein R1a, R2, R3, R4a, R4b and R4c are as defined herein.
Public/Granted literature
- US20200247824A1 HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE Public/Granted day:2020-08-06
Information query
